Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4

SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling

1997 • 10,943 citations

Cancer Statistics, 2006

2006 • 5,351 citations

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

2005 • 3,450 citations

Consed: A Graphical Tool for Sequence Finishing

1998 • 3,325 citations

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

2004 • 3,304 citations

A census of human cancer genes

2004 • 3,190 citations

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

2006 • 3,040 citations

Patterns of somatic mutation in human cancer genomes

2007 • 2,975 citations

Epidermal growth factor receptor mutations in lung cancer

2007 • 2,966 citations

Somatic mutations affect key pathways in lung adenocarcinoma

2008 • 2,653 citations

Targeted cancer therapy

2004 • 1,116 citations

Management of Cutaneous Melanoma

2004 • 830 citations

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

2001 • 721 citations

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

2005 • 262 citations

Roles of Erbb family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival

2002 • 191 citations

Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase

2008 • 184 citations

The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand

2005 • 184 citations

Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma

2009 • 152 citations

Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation

2007 • 150 citations

Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

1999 • 133 citations

Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant Melanoma

2008 • 122 citations

Somatic mutations of theERBB4kinase domain in human cancers

2005 • 112 citations

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer

2003 • 99 citations

Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer

2006 • 91 citations

Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis

2007 • 90 citations

Automating resequencing-based detection of insertion-deletion polymorphisms

2006 • 86 citations

The ErbB4 Growth Factor Receptor Is Required for Colon Epithelial Cell Survival in the Presence of TNF

2008 • 86 citations

Heterogeneous Patterns of FLT3 Asp835 Mutations in Relapsed de Novo Acute Myeloid Leukemia

2004 • 53 citations

Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells

2009 • 30 citations